| INTRODUC TI ON
Despite the survival and quality of life benefit of kidney transplantation versus dialysis, [1] [2] [3] [4] only one-third of the approximately 703 000
United States patients living with end stage renal disease (ESRD) have received a kidney transplant, of which ~30% are living donor transplants. 1 While transplant recipients have higher survival rates compared to dialysis patients, the relative survival advantage associated
with kidney transplantation varies depending on individual characteristics, such as age, sex, race, and comorbidities. 1, 4 While ESRD patients actively seek involvement in providers' decisions about their treatment options, 5 they are often uninformed about kidney transplantation and have limited knowledge about the absolute and relative mortality of kidney transplantation versus dialysis. [6] [7] [8] [9] [10] [11] Education about kidney transplantation should ideally occur in stage 4 chronic kidney disease (CKD) and continue throughout each step of the transplant process to give patients more opportunities to process treatment information and actively discuss treatment options with providers. However, in-depth conversations between providers and patients may be inadequate due to provider time constraints, limited educational resources with individualized risk information, and difficulties clearly informing patients about treatment options. [12] [13] [14] [15] Decision aids such as pamphlets, videos, or mobile applications can improve decision-making among patients faced with multiple options to treat their disease. 16, 17 When used with clinicians, shared decision aids can initiate more in-depth and individually tailored discussions about treatment options. 17 Given the barriers to transplant education among ESRD patients and the potential benefits of decision aids, we previously developed a shared patient-provider clinical decision aid called iChoose Kidney (iPad, iPhone, and website: www.ichoosekidney.emory.edu). 18 This decision aid displays individualized risk estimates of survival or mortality for transplantation versus dialysis and is designed for clinical providers to use with patients to better inform them about the clinical implications of their treatment options. While the tool was previously developed, 18 the effectiveness of the tool in improving patient knowledge of treatment options had not been tested in a rigorous manner.
We conducted a randomized controlled trial of the iChoose Kidney decision aid among patients undergoing evaluation for kidney transplantation at three major US transplant centers to analyze the effect of iChoose Kidney on improving patient knowledge about the benefits of kidney transplant compared to dialysis 19 ; we also measured the association with transplant access (waitlisting, living donor inquiries, and living or deceased donor kidney transplant). It was hypothesized that ESRD patients using iChoose Kidney during their transplant evaluation would have improved knowledge about the benefits of transplant and be more likely to pursue the steps to receive a kidney transplant compared to control participants.
| ME THODS

| Study overview and protocol
As previously described, the iChoose Kidney decision aid is a shared patient/provider mobile and web-based application that uses national surveillance data to provide individualized risk estimates of mortality and survival by treatment modality (dialysis vs. transplant; living vs. deceased donor transplant) based on patient characteristics. 18 Using a series of visual displays, providers are prompted to input demographic and clinical characteristics specific to a patient.
Once patient data are entered into the tool, iChoose Kidney communicates both absolute and relative risk estimates in written and graphic displays to increase patient and provider understanding of treatment benefit ( Figure 1 ).
ESRD patients were recruited into the randomized controlled trial (clinicaltrials.gov NCT02235571) between December 2014
and October 2015 at the time of evaluation for kidney transplant in One month prior to study start, providers were administered a provider baseline survey to assess provider demographics, previous use of mobile tools, and how often they discussed the survival benefit of transplant versus dialysis with patients. On the day of evaluation, trained research assistants administered a baseline survey for patients via iPad before the patients met with the transplant nephrologist or surgeon. Providers were blinded to questions asked in patient surveys. If randomized to the intervention, iChoose Kidney was used with patients during the transplant evaluation by either the transplant nephrologist or surgeon; physicians were instructed at study start to use the aid with the intervention patients, but were not specifically given a script about how to present the individualized risk estimates to patients. Given the nature of the intervention, neither patients nor providers were blinded to the study group assignment. After the intervention, follow-up data was collected from patients and providers at multiple time points (Figure 2 (Table S1 ). Evidence of face validity was assessed and established by these experts and pilot tested in a sample of patients.
Questions were developed following theory-based intervention guidelines 20, 21 and were intended to assess the underlying theoretical construct of knowledge about the relative and absolute risks of mortality with dialysis versus transplant and deceased versus living donor transplant. Patients were also asked to estimate their relative risk of mortality with dialysis versus transplant (on a scale from F I G U R E 2 Study schema of the iChoose Kidney randomized controlled trial depicting the study process and points of data collection for both control and intervention patients, and providers (transplant nephrologists or surgeons), 2014-2015 1-9) and whether they were (more, less, or equally likely) to die with dialysis compared to with a kidney transplant ( Table S1 ). The numerical portion of this two-part item was discarded from analyses as research assistants noted patient confusion about this question in the early weeks of the study. However, the last portion of the item (more, less, or equally likely) was still included in the knowledge score. Transplant knowledge difference from pre-to post-evaluation was calculated by subtracting the mean pre-survey from post-survey transplant knowledge scale scores and comparing the differences between intervention versus control participants. Additionally, we conducted pre-planned subgroup analyses by sex, race, health literacy, and numeracy.
Patients missing all nine items of the knowledge scale in either the pre-or post-survey were excluded from analyses (n = 27; 5.7%).
Additional sensitivity analyses were conducted to compare patients missing one or more knowledge items (n = 57) to patients with complete knowledge data (n = 386). Because health literacy and numeracy were different between those two populations, we categorized a missing item as incorrect (0 points) for these 57 patients when calculating transplant knowledge scores versus excluding them from analyses.
| Access to transplant (secondary endpoint)
Transplant access was defined a priori as a composite endpoint as having one of the following within one year of the patient's transplant evaluation: ≥1 living donor inquiry, placement on the kidney transplant waiting list, or receipt of a living or deceased donor transplant. Outcome data were abstracted from patients' electronic medical records (EMR) at study end.
| Decisional conflict (secondary endpoint)
Decisional conflict was measured via O'Connor's validated 10-item scale assessing personal perceptions of uncertainty in choosing options, modifiable factors contributing to uncertainty, and effective decision-making. 22 The O'Connor scale was selected for its emphasis on treatment option decisional conflict and use in previous studies among chronic disease patients. [23] [24] [25] The decisional conflict scale was included in patient baseline and follow-up surveys and consisted of 10 questions with responses being "Yes," "Unsure," or "No,"
valued at 0, 2, or 4 points, respectively. The 10 items were summed, divided by 10, and multiplied by 25 to calculate the decisional conflict score, ranging from 0 (no decisional conflict) to 100 (high decisional conflict).
26, 27
| Patient treatment preferences (secondary endpoint)
To assess whether the tool affected treatment preferences, patients were asked in baseline and follow-up surveys what type of treatment they preferred: hemodialysis, peritoneal dialysis, transplant, or unsure.
| Provider opinions (secondary endpoint)
In the immediate provider follow-up survey administered after each patient visit, we asked providers if they used estimates of patient survival or of mortality to communicate risk estimates to their patients and compared how often providers discussed the benefit of transplant versus dialysis and living donor versus deceased donor transplant by study group. In addition, we surveyed transplant nephrologist and surgeon preferences, opinions, and satisfaction in order to evaluate usability of iChoose Kidney among providers in a provider post-study follow-up survey ~3 months after the study ended (Table S2 ). Health literacy was measured using the Newest Vital Sign, sixitem scale (range: 0-6; categorized into low: 0-1, medium: 2-3, or high: 4-6). 28 Numeracy was evaluated using the Lipkus, 11-item scale (range: 0-11; categorized into low: 0-4, medium: 5-8, and high: 9-11). 29 These measures were selected as they were previously validated and appropriate for use among patients with limited literacy.
|
EMR data were extracted for several clinical variables: body mass index (categorized as >35 vs. ≤35 kg/m 2 ), history of comorbidities (diabetes, hypertension, and cardiovascular disease), low albumin level (<3.5 g/dL), dialysis modality at time of evaluation, and dialysis start date to calculate time on dialysis (in days). In the case of missing survey data, EMR data were also abstracted.
| Statistical analyses
Descriptive analyses of patient characteristics were conducted to evaluate differences between study arms at baseline using Pearson's chi-square tests and t-tests. A t-test was used to determine significance of the mean difference in differences in transplant knowledge from pre-to post-evaluation in intervention versus control patients and the pre-planned subgroups.
For secondary endpoints, chi-square tests were used to determine if the proportion of patients with access to transplant differed by study group, to examine whether the proportion of patients with decisional conflict scores that decreased, remained the same, and increased pre-to post-evaluation, and to assess differences in the proportion of patients who changed treatment preference pre-to post-evaluation by study group. Chi-square analyses were also used to assess if there was a difference in the number of times providers had the conversation about the survival benefit of transplant versus dialysis and of living versus deceased donor transplants by study group. Results were considered statistically significant at P < .05. SAS 9.4 (SAS Institute, Cary, NC) was used for all statistical analyses.
Based on a repeated measures design consisting of two groups of subjects, each measured at two time points, we estimated that a sample size of 420 (210 in the control and intervention arm) achieved 80% power to detect a difference between the intervention and control groups in the mean difference in differences in transplant knowledge of 0.71 points with a standard deviation of 2.0 at the two time points. This calculation assumed a correlation of 0.01 between baseline and follow-up measurements. The significance level (alpha) is 0.05 using a two-sided, two-sample t-test. Secondary outcomes were pre-planned, but the study was not specifically powered to detect statistical significance for these outcomes.
| RE SULTS
A total of 657 patients were screened for participation in the iChoose Kidney randomized controlled trial from December 2014
to October 2015 until the target sample size was reached; 187 patients were excluded, because they did not meet study inclusion criteria (n = 106) or declined to participate (n = 81). Of the 470 patients consented and randomized to use (intervention; n = 238) or not use (control; n = 232) iChoose Kidney during medical evaluation, 27 patients were excluded for missing data on all transplant knowledge items (primary outcome). The final study population included 443 patients (intervention; n = 226 and control; n = 217; Figure 3 ).
| Patient characteristics
Of the 443 eligible patients, the mean age was 50.6 (10.1) years, with 62.5% male, 47.9% African American, and 10.6% white Hispanic (Table 1 ). The majority of the patients had hypertension (79.0%) and reported having Medicare (49.7%) or private (52.6%) insurance (Table 1) . About one-third of our study population had not been on dialysis prior to evaluation (33.2%), with the remaining two-thirds of patients on dialysis for a median of 356 days (Q1-Q3: 162-1146). The overall mean health literacy and numeracy scores were 3.5 out of 6 (2.0) and 6.1 out of 11 (3.2), respectively (Table 1) .
| Measured outcomes
| Transplant knowledge
The mean transplant knowledge score pre-and post-evaluation for all patients improved from 5.06 (± 2.14) at baseline to 5.80 (± 1.92)
at follow-up (out of nine) with a mean difference of 0.74 (± 1.81).
Difference in transplant knowledge from pre-to post-evaluation was significantly higher among iChoose Kidney intervention a Percentages may not all add up to 100% due to missing data. Covariates with missing data include: race (n = 1); household income before taxes (n = 46); marital status (n = 5); educational level (n = 6); employment status (n = 8); self-rated health (n = 4); internet access (n = 3); social support (n = 44); time point first educated about transplant (n = 6); albumin level <3.5 g/dL (n = 16); health literacy (n = 6); numeracy (n = 8); kidney disease treatment preference (n = 5). b Measured at the time of transplant evaluation. c Includes Asian, American Indian/Alaskan Native, Native Hawaiian/Pacific Islander, Middle Eastern, East Indian, and multiracial. d Defined as at least one family member or friend accompanying the patient at the transplant evaluation. e Literacy score calculated using Newest Vital Sign, NVS, on a scale from 0 to 6. f Numeracy score calculated using the Lipkus scale, on a scale from 0-11.
TA B L E 1 (Continued)
TA B L E 2 Mean transplant knowledge scores (range: 0-9 points) pre-evaluation, post-evaluation, and differences (pre-to post-evaluation) stratified by selected patient characteristics according to the assigned study group in the iChoose Kidney Randomized Controlled Trial 
| Access to transplant
Among intervention patients, there were trends towards better access to kidney transplantation within one year of transplant evaluation, but results were not statistically significant (Table 3) .
Intervention patients were more often placed on the national wait- compared to control patients. The proportion of patients with at least one of the three access measures was not significantly higher among iChoose (n = 168; 74.3%) versus control (n = 155; 71.4%) patients (P = .37) ( Table 3) .
| Decisional conflict
Regardless of study group, the majority of patients' decisional conflict score remained the same pre-to post-evaluation (n = 238; 53.7%). Decisional conflict decreased after evaluation for 181 patients; there were no significant differences between intervention (n = 96; 42.5%) versus control (n = 85; 39.2%) patients (P = .48) (Table S3 ).
| Treatment preference
At baseline, the majority of patients reported a preference for transplant (n = 328; 74.0%) compared to hemodialysis (n = 56; 12.6%) or peritoneal dialysis (n = 37; 8.4%) ( Table 1) . About two-thirds (64.6%) of patients with a preference for transplant before their evaluation continued to select transplant as their preferred kidney disease treatment method after evaluation. The proportion of patients changing treatment preference from dialysis to transplant was not significantly different among iChoose (n = 19; 8.4%) versus control (n = 12; 5.5%) patients (P = .24) (Table S4 ).
| Provider opinions
Of providers who took the baseline surveys prior to study start (n = 34), 90% were nephrologists; 34% had been practicing for <5 years, 35% for 5-10 years, and 31% for >10 years. Prior to the study, only 38% of providers had ever utilized educational tools with pre-transplant patients on a mobile device or computer. Providers from all study sites reported discussing the benefit of transplant versus dialysis with 95% of intervention patients versus 90% of controls (P = .04) in the immediate follow-up provider survey, with providers most often communicating survival risk estimates (58%) to patients versus mortality (25%) or both (17%). The benefit of living versus deceased donor transplant was discussed with 91% of intervention versus 78% of control patients via results of the immediate follow-up provider survey (P < .0001).
Among providers surveyed 3 months after the study (n = 19)
in the post-study follow-up provider survey, all providers believed that patients were receptive to using iChoose Kidney, with 95% and 68% reporting that patients' understanding of the survival benefit of transplant versus dialysis and living donor versus deceased donor transplant improved, respectively, due to the use of the tool. In this survey, the majority of providers (89%) indicated they "always" discussed the survival benefit of transplant versus dialysis with patients during evaluation, compared to only 35% reporting this prior to study start in the provider baseline survey. At the three-month follow-up, almost all of the surveyed providers (95%) indicated that providers could benefit from implementing the tool as part of their regular practice. However, 21% of providers believed that "adding time to the appointment" was a barrier to using the tool. Nonetheless, 94% of providers indicated they had a moderate or strong intention of using iChoose Kidney after the study. 
| D ISCUSS I ON
The results of this randomized controlled trial suggest that the one week after evaluation. 35 A systematic review concluded that decision aids were effective in improving treatment option knowledge and clearer expectations of treatment risks and benefits. 17 In a recent pilot study among liver transplant candidates, both knowledge and attitudes about organ quality improved after exposure to a web-based decision aid on the topic. 36 Prior studies also suggest that comprehensive education of ESRD treatment options may not be uniformly distributed. 7, 14, 37, 38 38 It is unlikely that the use of a single educational intervention could improve access to transplantation. In Waterman et al.'s study of dialysis facility education practices, facilities using more than three transplant education strategies had higher rates of waitlisting. 14 The iChoose Kidney aid was one of several patient-level interventions used in a previous randomized controlled trial, the RaDIANT Community Study, which led to increased referral for transplant evaluation and reduced racial disparities in referral among dialysis patients in Georgia. 41 Future research should test whether a combined approach of iChoose Kidney and other interventions can affect transplant access.
| Study limitations
Our primary outcome of transplant knowledge about the survival benefit of transplant and dialysis was not externally validated; however, a multidisciplinary group of experts developed the survey and it was pilot tested prior to the study. Because patients had already 
| Study conclusions
The results of this multicenter, randomized controlled trial among ESRD patients attending a medical evaluation at three large US transplant centers provides support for the iChoose Kidney decision aid's effect in improving ESRD patient transplant knowledge and initiating provider-patient conversations about the survival benefits of transplant (vs. dialysis) and living donor (vs. deceased donor) transplant. Our findings also suggest the iChoose Kidney tool may not be effective enough in isolation to significantly impact patient behavior enough to improve access to kidney transplant.
